Source: European Medicines Agency (EU) Revision Year: 2016 Publisher: Olympus Biotech International Limited, 40 Upper Mount Street, Dublin 2, Ireland Tel +353 87 9278653, medicalinfo@olympusbiotech.com
Treatment of non-union of tibia of at least 9 month duration, secondary to trauma, in skeletally mature patients, in cases where previous treatment with autograft has failed or use of autograft is unfeasible.
Osigraft should be used by an appropriately qualified surgeon.
The recommended dose is one single administration in adults. Depending on the size of the bone defect, more than one 1 g vial of Osigraft may be required. The recommended maximum dose should not exceed 2 vials since efficacy in the treatment on non-unions requiring higher doses has not been established.
Osigraft is contraindicated in children and adolescents (less than 18 years old) and the skeletally immature (see section 4.3).
Intraosseous use.
The reconstituted product is administered by direct surgical placement at the non-union site in contact with the prepared bone surface. The surrounding soft tissues are then closed around the implant. Experience from controlled clinical trials is limited to stabilisation of the fracture by intramedullary nailing.
No case of overdose has been reported.
Shelf life: 3 years.
The reconstituted product should be used immediately.
Store in a refrigerator (2°C-8°C).
Powder in a glass vial (Type 1, borosilicate) sealed with a stopper (butyl rubber) and a crimp cap (aluminium).
The primary package is maintained sterile within a blister pack, comprised of two (inner and outer) plastic trays and lids.
Pack size of 1 vial.
Each vial of Osigraft is reconstituted with 2 to 3 ml of sterile 9 mg/ml sodium chloride solution (0.9% w/v) prior to use. Sterile sodium chloride solution for injection and contents of the Osigraft vial are transferred to a sterile bowl and mixed with a sterile spatula or curette. To avoid breakage, do not tap the bottom of the vial when transferring contents. After reconstitution, the single use suspension for implantation should be used immediately.
When reconstituted, Osigraft has the consistency of wet sand, which facilitates its implantation and placement at bone site defects.
Any unused product or waste material should be disposed of in accordance with local requirements.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.